Q (haiku): Is KRAS G12C more aggressive than G12D?

═ answer (success)
I can help you explore KRAS G12C and G12D mutation data in cBioPortal, but I need to clarify an important limitation upfront.

**I cannot directly answer whether one variant is "more aggressive" than the other** based on cBioPortal data alone, because:

1. **cBioPortal contains genomic data, not outcome data** — the database captures mutations and clinical attributes (age, stage, etc.), but does not systematically store prognostic endpoints (overall survival, recurrence-free survival, response to therapy) that would be needed to compare aggressiveness.

2. **Frequency ≠ Aggressiveness** — even if G12C appears in more advanced-stage patients or in a larger proportion of a cohort, correlation does not imply that the variant itself drives aggression; it could reflect sampling bias, cancer type distribution, or confounding variables.

3. **No built-in statistical comparison** — cBioPortal cannot run survival analyses or hazard ratio tests. Any p-value or outcome comparison would require external biostatistical analysis.

---

## What I *can* do:

- **Compare prevalence** of KRAS G12C vs G12D across cancer types in cBioPortal (e.g., "G12C is 30% of KRAS mutations in lung adenocarcinoma; G12D is 15%")
- **Show patient characteristics** associated with each variant in the database (age, stage, gender distributions)
- **Link you to cBioPortal's group comparison tool** to manually explore clinical attribute differences between G12C-mutant and G12D-mutant cohorts
- **Suggest external resources** (literature, OncoKB, ClinVar) that may have functional or clinical evidence about relative aggressiveness

**Would you like me to:**
1. Query the prevalence and clinical characteristics of KRAS G12C vs G12D in a specific cancer type?
2. Generate a group comparison link in cBioPortal so you can visually compare these cohorts?
3. Point you to relevant literature or knowledge base resources (OncoKB, PMID search)?

Let me know which direction would be most helpful for your research.